Skip to content

April 25, 2008


“Proud to support the effort to advance research on this devastating disease”

WASHINGTON, D.C. – Today, U.S. Senator Jim Inhofe (R-Okla.) announced that May of 2008 will be officially recognized as “National Cystic Fibrosis Awareness Month” after his legislation passed the Senate by Unanimous Consent last night.  Senator Patty Murray (D-Wash.) joined Inhofe in introducing the Cystic Fibrosis Awareness Resolution (S.Res.510) last month.
“It’s critical that my colleagues in the Senate know about cystic fibrosis’ life threatening nature, and that those who have the disease have a life-expectancy of just 37 years,” Inhofe said.  “Particularly for the people who live with the challenge of cystic fibrosis in Oklahoma, I am proud to support the effort to advance research on this devastating disease.  
Senator Inhofe also recognized the significant contributions of the cystic fibrosis community, saying, “For all the work the cystic fibrosis community has done to battle the disease, it is our responsibility to acknowledge that and create avenues for advancing progress.”
Robert J. Beall, President and CEO of the Cystic Fibrosis Foundation thanked Senator Inhofe for his commitment, “We are so pleased that [the Senators] are leading the way to spread awareness about cystic fibrosis.  Through our drug development pipeline, we are achieving significant progress in our search for new treatments and a cure for this disease.  With more people aware of CF and more support for critical research, we will surely reach our goal and find a cure.”
“We are honored to have the United States Senate recognize the hope in our fight against CF,” Beall said.
For the last 55 years, the 30,000 Americans who have cystic fibrosis have relied on the Cystic Fibrosis Foundation to fund and develop innovative care and research to address the disease. The Foundation has successfully delivered several life-extending drugs to patients, and more than 30 drugs are currently in development.

Next Article » « Previous Article